Robert Dreicer

Intermittent Androgen Deprivation Therapy for Metastatic Prostate Cancer

Androgen deprivation therapy (ADT) for initial management of patients with metastatic prostate cancer has been the standard of care for more than 70 years. The dramatic rise in patients diagnosed with prostate cancer, following the advent of prostate-specific antigen (PSA) testing in the late 1980s, increased the ranks of those who underwent prostate surgery and radiotherapy and those who were ultimately found to have biochemical PSA failure. Many patients subsequently received ADT, often in the nonmetastatic setting, and were exposed to prolonged testosterone suppression, which unmasked such …

Why Do Obese Men Have Lower PSA Concentrations

In men with newly diagnosed prostate cancer, obesity is associated with worse oncologic outcomes. A myriad of issues might contribute to this

Surveillance vs. Metastasis-Directed Therapy for Oligometastatic Prostate Cancer

Oligometastatic prostate cancer has been characterized in a variety of ways, including as an intermediate state of cancer spread between localized

Nivolumab plus Ipilimumab for Advanced Renal-Cell Carcinoma

For more than a decade, vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) such as suninitib and pazopanib have been

Adjuvant vs. Early Salvage Radiotherapy for High-Risk Prostate Cancer

Among the myriad controversies regarding the management of patients undergoing radical prostatectomy for locally advanced prostate cancer is the

Radiotherapy plus Androgen Deprivation for Recurrent Prostate Cancer

Of men who undergo radical prostatectomy for clinically organ-confined prostate cancer, 30% to 40% will experience prostate-specific antigen (PSA)

Prostatectomy vs. Observation for Localized Prostate Cancer

Evolving evidence from randomized trials assessing the utility of surgery versus surveillance for localized prostate cancer has provided mixed results.

Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Cabazitaxel is a second-generation taxane that was FDA approved to treat patients with metastatic castration-resistant prostate cancer (mCRPC) after it

Is There a Role for AR-V7 Testing in Prostate Cancer?

Among the multiple mechanisms proposed for continued stimulation of the androgen receptor (AR) in castration-resistant prostate cancer (CRPC) is the

How Active Should Active Surveillance Be for Prostate Cancer

Active surveillance (AS) is increasingly accepted as a standard of care for men with low-risk prostate cancer. However, consensus about how to